Septerna, Inc.
As of Oct 22, 2026, Septerna is in Stage 2, the uptrend phase, now in week 20 (since Jun 3, 2026). It closed at $40.88, 15.2% below its 52-week high and above its 200-day average, which is rising.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is SEPN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SEPN among Biotechnology54th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …54 | SEPN | Stage 2 · wk 20 | 94 | +6.3% |
Septerna: quick answers
What stage is Septerna in?
As of Oct 22, 2026, Septerna (SEPN) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 3, 2026 and is in week 20. What the four stages mean
Is Septerna in an uptrend?
Yes. Septerna is in a Stage 2 uptrend. It trades 29.5% above its 200-day average, which is rising.
How far is Septerna from its 52-week high?
Septerna closed at $40.88 on Oct 22, 2026, 15.2% below its 52-week high of $48.19. Its 52-week low is $18.10.
How has Septerna performed over the past year?
As of Oct 22, 2026, Septerna is up 91.8% over the past year and up 46.1% so far in 2026.
Which sector and industry is Septerna in?
Septerna is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.